Picture [LSA] – The Business Web Portal 650x89px
Document › Details

Uniqure N.V.. (8/24/17). "Press Release: Uniqure Announces Company Participation at Citi Healthcare Conference". Lexington, MA & Amsterdam.

Region Region Boston, MA
  Country United States (USA)
Organisations Organisation Uniqure N.V. (Nasdaq: QURE)
  Group Uniqure (Group)
  Organisation 2 Citigroup (Group)
Products Product Citi’s 12th Annual Biotech Conference 2017 Boston
  Product 2 gene therapy
Index term Index term Uniqure–Citigroup: investor conference, 201709 supply service Uniqure participates in Citi’s 12th Annual Biotech Conference in Boston
Persons Person Kapusta, Matthew (Uniqure 201612– CEO before interim CEO before CFO before AngioDynamics + Smith & Nephew Orthopaedics)
  Person 2 Cantor, Maria E. (Uniqure 201606– SVP IR + Communications before Ariad Pharmaceuticals + Genzyme)

Live webcast of gene therapy panel discussion on Thursday, September 7 at 11:00 am EDT

uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in a gene therapy panel discussion and host investor meetings during the Citi Healthcare Conference held in Boston from September 5-7, 2017.

Matt Kapusta, chief executive officer of uniQure, will participate on the analyst-moderated panel entitled, "Gene-Therapy Manufacturing and Regulatory - Challenges and Opportunities" on Thursday, September 7, 2017 at 11:00 am EDT. A live webcast of the panel discussion can be accessed through the link displayed in the Investor Section of the uniQure website at A replay of the webcast will be available within 24 hours following the event, and will remain available for at least two weeks.

About uniQure

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington's disease and cardiovascular diseases.

uniQure Contacts:

For Investors:

Maria E. Cantor
Direct: 339-970-7536
Mobile: 617-680-9452

Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79

For Media:

Tom Malone
Direct: 339-970-7558
Mobile: 339-223-8541

Record changed: 2017-10-07


Picture [LSA] – The Business Web Portal 650x89px

More documents for Uniqure (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top